AMGA applauded the Centers for Medicare & Medicaid Services’ (CMS’) decision to not move forward with the Medicare Part B Drug Demonstration.
In May, AMGA submitted comments to CMS outlining concerns that the proposal could hinder beneficiary access to needed medications while doing little to improve quality.
“AMGA appreciates that the administration considered stakeholder feedback from AMGA and others and will not move forward with this proposal,” said Donald W. Fisher, Ph.D., CAE, AMGA’s president and chief executive officer. “AMGA supports the transition to value-based payment and looks forward to working with the current and incoming administration on building a healthcare system that truly rewards quality of care, reduces cost, and advances population health.”
